Title: Association of lymphocyte subsets with the efficacy and prognosis of PD#1 inhibitor
therapy in advanced gastric cancer: results from a monocentric retrospective study
Version: 1 Date: 05 Dec 2023
Reviewer's report:
Authors have correctly changed some of the reviewer’s comments, albeit there are some caveats
that need to be addressed. Again, I congratulate the authors for this study, which will be very
useful in the clinical practice if, at my point of view, they differentiate the different patient
cohorts included.
Patients with dMMR (n=9) and pMMR (n=186) tumours should be analyzed separately. Also,
patients receiving chemotherapy plus IO (n=173) from patients receiving IO +/- anti-angiogenic
agents (n=22) should be distinctly addressed. Finally, a distinctive analysis should be added
separating patients receiving IO in the 1st line setting (treatment naïve patients, n=53) from
others (n=142).
Efficacy is reported if CR, PR or SD at the CT scan performed at 3 months. Nevertheless,
in patients receiving chemotherapy, SD at 3 months is normally achieved. This should be
considered: the term “efficacy” is too optimistic.
Differences in PFS lower than 1 months, although statistically significant, aren’t clinically
relevant. Although gastric cancer is an aggressive disease, differences lower than 1 months are
irrelevant in the 1st and 2nd line setting.
Finally, dMMR status should be defined only in those tumours that loose two of the 4 MMR
proteins. If only one protein is loosed, then the diagnosis should be confirmed by PCR.
Title: Association of lymphocyte subsets with the efficacy and prognosis of PD#1 inhibitor
therapy in advanced gastric cancer: results from a monocentric retrospective study
Version: 1 Date: 05 Dec 2023
Reviewer's report:
Authors have correctly changed some of the reviewer’s comments, albeit there are some caveats
that need to be addressed. Again, I congratulate the authors for this study, which will be very
useful in the clinical practice if, at my point of view, they differentiate the different patient
cohorts included.
Patients with dMMR (n=9) and pMMR (n=186) tumours should be analyzed separately. Also,
patients receiving chemotherapy plus IO (n=173) from patients receiving IO +/- anti-angiogenic
agents (n=22) should be distinctly addressed. Finally, a distinctive analysis should be added
separating patients receiving IO in the 1st line setting (treatment naïve patients, n=53) from
others (n=142).
Efficacy is reported if CR, PR or SD at the CT scan performed at 3 months. Nevertheless,
in patients receiving chemotherapy, SD at 3 months is normally achieved. This should be
considered: the term “efficacy” is too optimistic.
Differences in PFS lower than 1 months, although statistically significant, aren’t clinically
relevant. Although gastric cancer is an aggressive disease, differences lower than 1 months are
irrelevant in the 1st and 2nd line setting.
Finally, dMMR status should be defined only in those tumours that loose two of the 4 MMR
proteins. If only one protein is loosed, then the diagnosis should be confirmed by PCR.
Please review this paper.
user
Title: Association of lymphocyte subsets with the efficacy and prognosis of PD#1 inhibitor
therapy in advanced gastric cancer: results from a monocentric retrospective study
Version: 1 Date: 05 Dec 2023
Reviewer's report:
Authors have correctly changed some of the reviewer’s comments, albeit there are some caveats
that need to be addressed. Again, I congratulate the authors for this study, which will be very
useful in the clinical practice if, at my point of view, they differentiate the different patient
cohorts included.
Patients with dMMR (n=9) and pMMR (n=186) tumours should be analyzed separately. Also,
patients receiving chemotherapy plus IO (n=173) from patients receiving IO +/- anti-angiogenic
agents (n=22) should be distinctly addressed. Finally, a distinctive analysis should be added
separating patients receiving IO in the 1st line setting (treatment naïve patients, n=53) from
others (n=142).
Efficacy is reported if CR, PR or SD at the CT scan performed at 3 months. Nevertheless,
in patients receiving chemotherapy, SD at 3 months is normally achieved. This should be
considered: the term “efficacy” is too optimistic.
Differences in PFS lower than 1 months, although statistically significant, aren’t clinically
relevant. Although gastric cancer is an aggressive disease, differences lower than 1 months are
irrelevant in the 1st and 2nd line setting.
Finally, dMMR status should be defined only in those tumours that loose two of the 4 MMR
proteins. If only one protein is loosed, then the diagnosis should be confirmed by PCR.
assistant